Navigation Links
Quest Diagnostics India Recognized as Laureate by the Computerworld Honors Program
Date:6/3/2009

Quest4Health.com Lauded in Healthcare Category for 'Visionary Application of Information Technology to Promote Positive Social and Economic Progress'

MADISON, N.J., June 3 /PRNewswire-FirstCall/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its subsidiary Quest Diagnostics India Pvt. Ltd. has been recognized as a Laureate by the International Data Group's (IDG) Computerworld Honors Program. The award, honoring the company's leadership in the healthcare category for using information technology to benefit society, recognized the contributions that its comprehensive internet-based portal www.Quest4Health.com has made toward the improved health of the people of India.

"Each year, the Computerworld Honors Program seeks to recognize organizations, from a variety of sectors, for their ongoing efforts to utilize technology in order to benefit society," said Ron Milton, Chairman of the Board of Trustees for the Computerworld Information Technology Awards Foundation and Executive Vice President of Computerworld. "We congratulate Quest Diagnostics for introducing a visionary application of information technology to the healthcare industry that demonstrates a commitment to the people of India, an informed understanding of the needs of a diverse population, and an ability to foster a community's improved health through innovative technologies."

Founded by International Data Group (IDG) in 1988, the Computerworld Honors Program is governed by the not-for-profit Computerworld Information Technology Awards Foundation. Each year, the program's Chairmen's Committee, a group of 100 Chairmen/CEOs of global technology companies, nominates individuals and organizations around the
'/>"/>

SOURCE Quest Diagnostics Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. New From the Heinz Family Philanthropies: 10 Questions and Valuable Answers to Help Families Manage Long-Term Care
2. Quest Diagnostics Announces Early Tender Results of Offer to Purchase Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes
3. Quest Diagnostics HemoCue AB Subsidiary to Add Avie(TM) Hemoglobin A1c to Diabetes Point-of-Care Test Suite
4. United States Patent and Trademark Office Accepts CoolTouch's Re-examination Request for Cynosure '873 Patent
5. Quest Diagnostics Introduces First Comprehensive Laboratory Test To Analyze KRAS, NRAS, and BRAF Gene Mutations in Reflex Testing Service
6. Biologists Question Animal Brain Size Theory
7. New From the Heinz Family Philanthropies: 10 New Questions Families Should Ask Before Choosing Long-Term Care
8. Study questions whether Ontarios primary health care reforms serve the sick and poor
9. Rarely Used Closed Doors Slammed Again in U.S. Senate Health Care Reform; Sen. Max Baucus Must Publicly Answer 10 Questions About Mandatory Purchase of Health Insurance
10. Heinz Family Philanthropies (www.heinzfamily.org) Release Questions Families Should Ask About Long-Term Care - 10 Questions to Answer...(www.tenquestionstoanswer.org)
11. Ted Karkus Admits to Financial Relationship With Dr. Richard A. Rosenbloom; Demonstrates Pattern of Improper Influence, Unethical Behavior, Falsification and Distortion; Company Questions What Else Karkus May Be Hiding From Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 4Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 5Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 6Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 7Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 8Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 9Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 10Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 11Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 12Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 13Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 14Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 15Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 16Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 17Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 18News brief 3A Estrogen receptor alpha breast cancer patients and tamoxifen response 62159 1New stress related gene modulates high blood pressure in mice and men 62157 1New stress related gene modulates high blood pressure in mice and men 62157 2Type 1 Diabetes May Have a New Foe 62155 1Type 1 Diabetes May Have a New Foe 62155 2Type 1 Diabetes May Have a New Foe 62155 3